Legal & General Group
CMPI

Legal & General Group’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Legal & General Group’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-876
Closed -$11K – 3735
2021
Q1 		$11K Buy
876
+355
+68% +$5.05K ﹤0.01% 3363
2020
Q4 		$8K Hold
521
– – ﹤0.01% 3404
2020
Q3 		$6K Buy
+521
New +$6.68K ﹤0.01% 3372

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Legal & General Group's CMPI Position: Q2 2021 in Review

Legal & General Group sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2021, closing a stake of 876 shares — an estimated $11K sold.

Legal & General Group first reported a position in CMPI in Q3 2020 and held it in 3 quarters. The position peaked at $11K in Q1 2021. 34 funds tracked by Wall St. Rank hold CMPI as of Q2 2021.

  • Legal & General Group reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 876 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $11K.
  • Legal & General Group first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Legal & General Group's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $11K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.